Merz Therapeutics GmbH, a global leader in neurology-focused specialty pharmaceuticals, today announced the opening of its new affiliate in Warsaw, Poland. This strategic expansion marks a major milestone in the company’s ongoing global growth and underlines its long-term commitment to improving patient care, supporting healthcare professionals, and advancing therapeutic innovation across Central and Eastern Europe.
By establishing a direct local presence, Merz Therapeutics assumes full operational responsibility for its activities in Poland, reinforcing its dedication to strengthening relationships with the medical community and delivering greater value to patients and partners alike.
A Strategic Step in Regional Growth
Poland has long been recognized as a key market within Central and Eastern Europe, not only for its dynamic healthcare system but also for its growing focus on neurological disorders and patient access to advanced treatments. For Merz Therapeutics, opening an affiliate in the country represents both a strategic and symbolic step — one that enhances its ability to respond to local needs while aligning with its global vision of helping patients live better lives.
“Establishing our own affiliate in Poland marks another important milestone in our growth journey,” said Andrea von der Lippe, President, Region International Markets at Merz Therapeutics. “Our direct presence will allow us to work even more closely with the Polish medical community, ensuring continuity for patients while also creating the foundation for sustainable growth.”
The new affiliate will enable Merz Therapeutics to tailor its operations more effectively to the Polish healthcare landscape, where demand for innovative neurological and movement disorder therapies continues to rise. The company will focus on supporting physicians and patients through educational initiatives, evidence-based collaboration, and increased access to Merz’s portfolio of proven and emerging treatments.
Building on a Strong Foundation
Merz Therapeutics’ journey in Poland began years ago through a successful partnership with Egora, which played a crucial role in establishing and expanding the company’s presence in the market. This collaboration has laid the groundwork for Merz’s next phase of growth, and the company has expressed its deep gratitude for Egora’s contributions to developing the business locally.
While Merz Therapeutics now transitions to direct management, the company has ensured seamless operational continuity. Product distribution will continue through Cefarm, one of Poland’s leading pharmaceutical distributors, ensuring uninterrupted access to Merz Therapeutics’ medicines for patients and healthcare providers.
This continuity is central to Merz’s mission of reliability and patient focus — ensuring that the transition to direct operations strengthens, rather than disrupts, ongoing relationships and care pathways.
A Commitment to Patients and Partnerships
The new affiliate underscores Merz Therapeutics’ philosophy of “Advancing Patient Care Together”, which emphasizes collaboration, trust, and shared purpose with the healthcare community. The company’s decision to establish a full affiliate in Poland is driven by its belief that local engagement leads to better outcomes — both for patients and for the medical ecosystem as a whole.
By operating directly, Merz Therapeutics can better understand the needs of Polish healthcare professionals, engage in closer dialogue with key opinion leaders, and adapt its strategies to reflect the realities of clinical practice in the country. This local insight will also enable the company to support educational programs, clinical partnerships, and research initiatives that advance the field of neurology and movement disorders.
“Poland’s healthcare landscape is rapidly evolving, with growing emphasis on innovative therapies and patient-centered care,” noted von der Lippe. “With our new affiliate, Merz Therapeutics is better positioned to be an active, responsible, and forward-thinking partner to the Polish medical community.”
Leadership and Vision: A New Chapter for Merz Therapeutics Poland
To lead this important new chapter, Merz Therapeutics has appointed Jolanta Dilling-Sulimierska as General Manager, Merz Therapeutics Poland. A seasoned leader with extensive experience in the pharmaceutical sector, Dilling-Sulimierska brings a deep understanding of the Polish healthcare system and a proven record of fostering growth through collaboration and innovation.
In her new role, she will be responsible for developing the local organization, strengthening partnerships with stakeholders, and expanding access to Merz Therapeutics’ portfolio of treatments.
“I am honored to take on this role and excited to lead Merz Therapeutics’ new chapter in Poland,” said Jolanta Dilling-Sulimierska. “Our focus will be on supporting patients and healthcare professionals through collaboration, education, and the responsible growth of our therapies. Together with our partners, we aim to make a real difference in patient care.”
Her leadership will play a key role in deepening the company’s local engagement — from building a motivated and skilled team to ensuring that Merz’s core values of integrity, innovation, and empathy are reflected in every interaction with patients, clinicians, and partners.
Empowering the Future of Neurology and Patient Care
As a global leader in specialty neurology, Merz Therapeutics focuses on developing and delivering treatments that address some of the most challenging neurological conditions, including movement disorders such as spasticity, dystonia, and sialorrhea, as well as other medical conditions that significantly impact quality of life.
By bringing its expertise directly to Poland, the company aims to help more patients access effective, science-backed therapies while also supporting the continued education of medical professionals. The new affiliate will serve as a hub for collaboration — connecting local healthcare providers, researchers, and institutions with Merz Therapeutics’ international network of scientific expertise.
In addition to expanding access to its established therapies, Merz Therapeutics plans to explore opportunities for participation in clinical research and real-world evidence initiatives within Poland. These efforts align with the company’s broader commitment to innovation and evidence-based medicine, ensuring that new treatments are both effective and accessible to those who need them most.
Reinforcing a Global Vision Through Local Strength
The establishment of Merz Therapeutics Poland reflects the company’s global strategy to strengthen its presence in key markets through local empowerment and direct engagement. This approach allows the company to adapt to regional healthcare priorities while maintaining its global standards of quality, compliance, and patient-centered excellence.
By investing in local operations, Merz Therapeutics is reaffirming its belief that meaningful progress in healthcare happens when global expertise meets local insight.
As the new affiliate in Warsaw begins operations, the company’s message is clear: Merz Therapeutics is here to stay, to grow, and to make a lasting impact on patients’ lives in Poland and beyond.
“Our commitment to patients is what drives every decision we make,” concluded von der Lippe. “With our new affiliate in Poland, we are not only expanding our geographical footprint — we are deepening our promise to help people live better, more fulfilling lives.”
